Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)-Reference-Cited by-同舟云学术

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

Published:2023-08 Issue:8 Volume:18 Page:1031-1041
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Cornelissen Robin,Prelaj Arsela,Sun Sophie,Baik Christina,Wollner Mirjana,Haura Eric B.,Mamdani Hirva,Riess Jonathan W.,Cappuzzo Federico,Garassino Marina C.,Heymach John V.,Socinski Mark A.,Leu Szu-Yun,Bhat Gajanan,Lebel Francois,Le Xiuning

Funder

Spectrum Pharmaceuticals

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives;Mazières;J Clin Oncol,2013

2. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas;Shigematsu;Cancer Res,2005

3. Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2;Takeda;Oncotarget,2018

4. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers;Subramanian;Oncologist,2019

5. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors;Wang;Cancer Cell,2006

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10

2. NRG1 Gene Fusions—What Promise Remains Behind These Rare Genetic Alterations? A Comprehensive Review of Biology, Diagnostic Approaches, and Clinical Implications;Cancers;2024-08-05

3. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22

4. Current status of molecular diagnostics for lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-06-27

5. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases;International Journal of Molecular Sciences;2024-06-26